Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07627191 | 1 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
| NCT07419841 | 1 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Unknown mechanism |
| NCT06728293 | — | Effect of the HCC Liver-Link Intervention | Unknown mechanism |
| NCT07628751 | — | A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC | Unknown mechanism |
| NCT06066138 | 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | PD-L1 -- immune checkpoint inhibitor (atezolizumab) |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 39 |
| Tianjin Medical University Cancer Institute and Hospital | 16 |
| Second Affiliated Hospital of Guangzhou Medical University | 16 |
| Fudan University | 16 |
| Tongji Hospital | 13 |
Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Aug 2026 | NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors |
| Jul 1, 2026 | NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma | PD-1 -- immune checkpoint inhibitor (cemiplimab) +/- CTLA-4 inhibitor (fianlimab) |
| Jun 30, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
| Jun 2026 | NCT07587034 | HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer | VEGFR2 -- tyrosine kinase inhibitor (apatinib); PD-1 -- immune checkpoint inhibitor (camrelizumab) |
| May 29, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | MAGE-A1 + HLA-A*02:01 -- bispecific T-cell engager |
| May 1, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | PD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog |
| Apr 30, 2026 | NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | Chemotherapy (FOLFOX) + PD-1 inhibitor + VEGF inhibitor + TACE -- combination therapy |
| Apr 14, 2026 | NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | ROCK2 -- selective ROCK2 inhibitor plus VEGF -- anti-angiogenic antibody |
You've seen the hepatocellular carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.